Developing antibodies to target specific cancer mutations
A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project ID | NIH-11077173 on NIH RePORTER |
What this research studies
This research focuses on creating T cell receptor mimic antibodies that specifically target KRAS mutations, particularly the KRASG12D variant. Using innovative technology, the project aims to enhance the effectiveness of immunotherapies by developing antibodies that can differentiate between cancerous and normal cells. This approach seeks to improve treatment precision and reduce side effects for patients with cancers associated with these mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that harbor KRASG12D mutations.
Not a fit: Patients without KRAS mutations or those with cancers not associated with this specific mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with fewer side effects.
How similar studies have performed: Similar research approaches have shown promise in targeting specific mutations in cancer therapies, indicating potential for success in this novel application.
Where this research is happening
Branford, UNITED STATES
- Abbratech, INC. — Branford, United States (Active)
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.